D02 Discrepancies in reporting the upper CAG repeat allele between a central EHDN and local laboratories for centres participating in the REGISTRY project

Quarrell, O W J; Dumoulin, C; Handley, O; Ramos-Arroyo, M; Biunno, I; Bauer, P; O'Donovan, K; Peppa, N; Landwehrmeyer, G B
September 2010
Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA20
Academic Journal
Aim The European Huntington's Disease Network REGISTRY project analyses CAG repeat length measurements centrally which can be compared with the original laboratory result held at the local study site from 15 countries. We aimed to assess the extent of the discrepancies between duplicate results on the same sample obtained between January 2004 and June 2009. Methods We subtracted the result reported by the central EHDN laboratory, BioRep, from that obtained at the local laboratory. We assessed the impact of the discrepancy at the clinically significant boundaries of 35–36 repeats and 39–40 repeats. We then re-analysed the data using a proposed acceptable measurement error of ±1 repeat for results ≤42 repeats and ±3 repeats for results ≥43 repeats. In both cases, we will present results anonymously for 10 countries which contributed more than 20 samples. We compared duplicate results for 348 samples analysed by BioRep and the Tübingen laboratory. Results The results between BioRep and the local laboratory were discordant in 672 (51%) of the cases; in 52 (4%) cases, this resulted in a change at one of the clinical boundaries; and in five (0.4%) cases there was a potential misdiagnosis, one of which can be explained by a labelling error. When the data were re-analysed using a proposed acceptable measurement error, the number of discrepancies reduced to 129 (9.7%). Analysis of the upper allele for the 348 duplicate samples analysed at both BioRep and Tübingen gave a discrepancy rate of 6.9% but complete concordance when the proposed acceptable measurement error was used. Conclusions Clinicians need to be aware of a measurement error when CAG results are reported. We strongly recommend that service laboratories should participate in external quality assessment schemes but in addition, should use known standards regularly to calibrate their results.


Related Articles

  • Discrepancies in reporting the CAG repeat lengths for Huntington's disease. Quarrell, Oliver W; Handley, Olivia; O'Donovan, Kirsty; Dumoulin, Christine; Ramos-Arroyo, Maria; Biunno, Ida; Bauer, Peter; Kline, Margaret; Landwehrmeyer, G Bernhard // European Journal of Human Genetics;Jan2012, Vol. 20 Issue 1, p20 

    Huntington's disease results from a CAG repeat expansion within the Huntingtin gene; this is measured routinely in diagnostic laboratories. The European Huntington's Disease Network REGISTRY project centrally measures CAG repeat lengths on fresh samples; these were compared with the original...

  • Spinocerebellar Ataxia Type 2 (SCA2): Clinical Features and Genetic Analysis. Léon Mutesa; Geneviève Pierquin; Karin Segers; Jean François Vanbellinghen; Laetitia Gahimbare; Vincent Bours // Journal of Tropical Pediatrics;Oct2008, Vol. 54 Issue 5, p350 

    Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease that results from the expansion of an unstable trinucleotide CAG repeat encoding for a polyglutamine tract. In normal individuals, alleles contain between 14 and 31 CAG repeats, whereas the pathological...

  • F10 Correlations between functional measures, voluntary and involuntary motor symptoms in HD -multivariate analysis of cross-sectional and longitudinal registry data. Waters, S; Tedroff, J; Waters, N // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA25 

    Background The UHDRS motor section is composed of 31 items related to different aspects of the motor symptoms. These are heterogeneous in terms of functional impact, course of progression, and relation to pathological changes. Aims The present study is aimed at investigating the correlational...

  • D01 Updating of guidelines for the molecular genetic predictive test in Huntington's disease (1994). MacLeod, R; Tibben, A; Frontali, M // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA19 

    Background Guidelines for the molecular genetic predictive testing in Huntington's disease (HD) were issued in 1994, soon after the discovery of the gene. Since then, the research on HD has made remarkable advancements and a considerable amount of experience was acquired by centres offering the...

  • A preliminary case study of androgen receptor gene polymorphism association with impulsivity in women with alcoholism. Mettman, Daniel J.; Butler, Merlin G.; Poje, Albert B.; Penick, Elizabeth C.; Manzardo, Ann M . // Advances in Genomics & Genetics;2014, Vol. 4, p5 

    Objective: The androgen receptor (AR) gene, located on the X chromosome, contains a common polymorphism involving cytosine-adenine-guanine (CAG) repeats, which impacts disease and could contribute to the unequal sex ratio in alcoholism. CAG repeats in the AR gene are known to correlate with...

  • Associations between androgen receptor CAG & GGN repeat polymorphism & recurrent spontaneous abortions in Chinese women. Zhang Chuan; Dang Jie; Xu Hao; Bao Junhua; Guo Mengjing; Pei Liguo; Yan Yousheng; Lu Hong; Huo Zhenghao // Indian Journal of Medical Research;May2014, Vol. 139 Issue 5, p730 

    Background & objectives: Recurrent spontaneous abortion (RSA) is a reproductive problem that occurs in women in reproductive age with a frequency of 1-3 per cent. Previous studies have reported high levels of serum androgens to be associated with RSAs. At the molecular level, the effect of...

  • Androgen receptor gene repeats and indices of obesity in older adults. Gustafson, D R; Wen, M J; Koppanati, B M // International Journal of Obesity & Related Metabolic Disorders;Jan2003, Vol. 27 Issue 1, p75 

    OBJECTIVE: To examine the relationship between GGN and CAG trinucleotide repeat polymorphisms in the androgen receptor (AR) gene and indices of obesity in older Caucasian adults. DESIGN: A cross-sectional study. SUBJECTS: Ninety-nine healthy men (age 51 - 93 y) and 113 healthy postmenopausal...

  • F02 Observing Huntington's disease (HD): the European Huntington's Disease Network's REGISTRY.  // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA23 

    Background HD is relatively rare. Thus we need advanced, multi-centre, multi-national research frameworks to study simultaneously multiple complementary aspects of HD. Methods/techniques First cross-sectional data cut of the first 1766 participants from 13 European countries of REGISTRY, the...

  • L02 Prescription patterns for Huntington's disease in Europe: results from the REGISTRY observational study. Mestre, T; Coelho, M; Ferreira, J J // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA48 

    Background There is a wide range of therapeutic interventions proposed for the symptomatic treatment of Huntington's disease (HD). However, the majority of therapeutic decisions are supported by a low level of evidence. Aims To characterise the patterns of prescription and therapeutic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics